Neuromuscular Disorders

Apitegromab for the treatment of SMA 2:49
Apitegromab for the treatment of SMA
Gabriele Siciliano • 15 Jun 2021
Reduced safety factor in the pathogenesis of autoimmune and congenital myasthenic syndromes 2:37
Reduced safety factor in the pathogenesis of autoimmune and congenital myasthenic syndromes
Hakan Cetin • 23 Jun 2021
Presynaptic vs postsynaptic genetic mutations in severity of neuromuscular disease 1:24
Presynaptic vs postsynaptic genetic mutations in severity of neuromuscular disease
David Beeson • 8 Jun 2021
Collaboration between neurology and palliative care services in ALS 2:06
Collaboration between neurology and palliative care services in ALS
David Oliver • 11 Jun 2021
Robots for rehabilitation in neuromuscular disorders 3:26
Robots for rehabilitation in neuromuscular disorders
Gabriele Siciliano • 15 Jun 2021
Prevention of maternal antibody-mediated diseases 2:23
Prevention of maternal antibody-mediated diseases
Angela Vincent • 8 Jun 2021
Aspects of fetal and adult AChR function that remain unanswered 1:23
Aspects of fetal and adult AChR function that remain unanswered
David Beeson • 8 Jun 2021
Therapeutic monoclonal antibodies to prevent trans-placental transfer of pathogenic antibodies 5:46
Therapeutic monoclonal antibodies to prevent trans-placental transfer of pathogenic antibodies
Angela Vincent • 8 Jun 2021
Fetal and adult AChRs in congenital myasthenic syndromes in mice and humans 3:07
Fetal and adult AChRs in congenital myasthenic syndromes in mice and humans
David Beeson • 8 Jun 2021
Palliative care improves QoL in advanced neurodegenerative disorders 4:46
Palliative care improves QoL in advanced neurodegenerative disorders
David Oliver • 11 Jun 2021
Important considerations for the management of neuromuscular disorders 3:06
Important considerations for the management of neuromuscular disorders
Gabriele Siciliano • 15 Jun 2021
Should placebo-controlled trials be used in neuromuscular disease? 1:38
Should placebo-controlled trials be used in neuromuscular disease?
Nizar Souayah • 13 Apr 2021
The expanding treatment landscape for myasthenia gravis 2:11
The expanding treatment landscape for myasthenia gravis
James F. Howard Jr. • 7 Apr 2021
REGAIN study and extension trial of eculizumab in myasthenia gravis 1:34
REGAIN study and extension trial of eculizumab in myasthenia gravis
James F. Howard Jr. • 7 Apr 2021
Concomitant immunosuppressive therapy in gMG patients on the REGAIN extension study 1:02
Concomitant immunosuppressive therapy in gMG patients on the REGAIN extension study
James F. Howard Jr. • 7 Apr 2021
Impact of fcRn inhibitors on IgG-mediated autoimmune disorders 0:45
Impact of fcRn inhibitors on IgG-mediated autoimmune disorders
James F. Howard Jr. • 7 Apr 2021
The content of VJNeurology is intended for healthcare professionals